Skip to main content
. 2023 Nov 22;19:765–778. doi: 10.2147/VHRM.S429995

Table 6.

Antiplatelet Therapy in Patients with Acute Ischemic Heart Disease Who Had an ST-Elevation Myocardial Infarction, Non-ST-Elevation Myocardial Infarction or Aortocoronary Bypass

Clinical Situation Intervention
All patients:
  • 75–100 mg/day ASA (or 75 mg/day clopidogrel)

 PCI to place a stent:
  • DAPT with 75–325 mg/day ASA + 75 mg/day clopidogrel (or prasugrel 10 mg/day if <75 years and >60 kg, or 90 mg BID ticagrelor) for 6 months if chronic coronary syndrome, 12 months if ACS (can be reduced if high bleeding risk case by case)

  • single antiplatelet therapy thereafter

 PCI to place a stent with atrial fibrillation or flutter:
  • Oral anticoagulation (VKA or DOAC) + DAPT (100 mg/day ASA + 75 mg/day clopidogrel) for up to 1 month depending on hemorrhagic risk.

  • oral anticoagulation (DOAC/VKA) + single antiplatelet therapy (ASA or clopidogrel) until 1 year

  • oral anticoagulation thereafter

 PCI to place a stent and intraventricular thrombosis:
  • VKA for 6 months until complete resolution of the thrombosis. The duration of DAPT should be decided on a case-by-case basis

Abbreviations: ACS, acute coronary syndrome; ASA, acetylsalicylic acid; BID, twice daily; DAPT, double antiplatelet therapy; DOAC, direct oral anticoagulant; PCI, percutaneous coronary intervention; VKA, vitamin K antagonists.